Feedback Plc
Result of Annual General Meeting and
Commercial Update
Feedback plc (AIM: FDBK, "Feedback" or the
"Company"), the clinical infrastructure specialist, announces that
at the Annual General Meeting ("AGM") held today all resolutions,
including resolutions 1 to 4 pertaining to the Company's
Fundraising as announced on 4 November 2024, were duly passed,
details of the number of votes cast are detailed below.
Share Capital
Reorganisation
Following the approval of the Fundraising
Resolutions (resolutions 1 - 4 below), each of the Company's
13,334,659 Existing Ordinary Shares of 50 pence each will be
subdivided into one New Ordinary Share of one penny and one
Deferred Share of 49 pence in accordance with Resolution 1 and 2.
The New Ordinary Shares arising on implementation of the
subdivision will have the same rights as the Existing Ordinary
Shares, including voting and
other rights.
Commercial
Update
Further to the Company's announcement on 4
November 2024, the Company is pleased to confirm that it has now
entered into a memorandum of understanding with its partner and an
NHS Trust to implement a pilot for a novel 'Neighbourhood
Diagnostics Solution' that combines Bleepa with its partner's
technology to streamline NHS diagnostic and pathway referrals
between primary care, CDCs and secondary care. Following
integration of Bleepa with its partner's technology interface, the
pilot is expected to go live in a hospital trust setting in Q1
2025. The Company and its partner are actively building interest in
the solution and look forward to providing further updates in due
course.
The Pilot will act as a reference site for
national policy and provide a platform from which to launch focused
engagement with the central NHS and government with the intention
of positioning a business case for wider rollout aligned to the
Spring Budget. Together with its partners Feedback aims to
demonstrate a new technical infrastructure and operating model for
the NHS, underpinning the Secretary of State's vision for a
Neighbourhood Health Service.
Additionally the Company is in dialogue with a
number of ICBs regarding use of Bleepa as a Diagnostic
Enhanced Advice and Guidance platform under the Elective
Recovery Fund.
Total Voting
Rights
Further to the announcement on 4 November
2024, Admission of the New Ordinary Shares is expected to take
place at 8:00 a.m. on 29 November 2024.
On Admission, the issued share capital of the
Company will consist of 43,814,779 Ordinary Shares with one
voting right each. The Company does not hold any ordinary shares in
treasury. Therefore, the total number of ordinary shares and voting
rights in the Company will be 43,814,779. With effect from
Admission, this figure may be used by Shareholders in the Company
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the share capital of the Company under
the FCA's Disclosure Guidance and Transparency Rules.
Results of
AGM
The number of votes cast for and against each
of the resolutions proposed, and the number of votes withheld were
as follows:
|
Resolution
|
Votes for*
|
% of votes cast**
|
Votes against
|
% of votes cast***
|
Votes withheld***
|
Total votes cast****
|
|
Ordinary Resolution
|
|
|
|
|
|
|
|
1. To authorise the Share Capital
Reorganisation of the Company.
|
6,817,892
|
96.70%
|
233,055
|
3.31%
|
12,535
|
7,050,947
|
|
Special Resolution
|
|
|
|
|
|
|
|
2. To amend the articles of association of the
Company in connection with the Share Capital
Reorganisation.
|
6,817,892
|
96.70%
|
233,055
|
3.31%
|
12,535
|
7,050,947
|
|
Further Ordinary Resolution
|
|
|
|
|
|
|
|
3. To authorise the directors to allot equity
securities generally in connection with the fundraising.
|
6,817,892
|
96.70%
|
233,055
|
3.31%
|
12,535
|
7,050,947
|
|
Further Special Resolution
|
|
|
|
|
|
|
|
4. To authorise the directors to dis-apply
pre-emption rights on a limited basis in connection with the
fundraising.
|
6,771,226
|
96.03%
|
279,721
|
3.97%
|
12,535
|
7,050,947
|
|
Further Ordinary Resolutions
|
|
|
|
|
|
|
|
5. To receive the Annual Report and Accounts
for the year ended 31 May 2024, together with the Directors'
reports and auditor's report.
|
7,050,844
|
100.00%
|
103
|
0.00%
|
12,535
|
7,050,947
|
|
6. To receive the Directors' Remuneration
Report of the Company for the year ended 31 May 2024.
|
6,231,723
|
91.32%
|
592,440
|
8.68%
|
239,319
|
6,824,163
|
|
7. To re-elect Professor Rory Shaw as a
director of the Company.
|
6,771,226
|
99.28%
|
49,285
|
0.72%
|
242,971
|
6,820,511
|
|
8. To re-elect Dr. Tom Oakley as a director of
the Company.
|
7,044,992
|
99.97%
|
2,303
|
0.03%
|
16,187
|
7,047,295
|
|
9. To re-elect Anesh Patel as a director of the
Company.
|
7,017,492
|
99.58%
|
29,803
|
0.42%
|
16,187
|
7,047,295
|
|
10. To re-elect Adam Denning as a director of
the Company.
|
6,046,532
|
91.08%
|
592,224
|
8.92%
|
592,224
|
6,638,756
|
|
11. To re-elect Annemijn Eschauzier as a
director of the Company.
|
6,409,619
|
99.96%
|
2,353
|
0.04%
|
651,510
|
6,411,972
|
|
12. To re-elect Philipp Prince as a director of
the Company.
|
6,046,532
|
91.08%
|
592,224
|
8.92%
|
424,726
|
6,638,756
|
|
13. To re-appoint Price Bailey LLP as auditor
of the Company.
|
7,047,192
|
100.00%
|
103
|
0.00%
|
16,187
|
7,047,295
|
|
14. To authorise the directors to determine the
fees payable to the auditor.
|
7,050,894
|
100.00%
|
53
|
0.00%
|
12,535
|
7,050,947
|
|
15. To authorise the directors to allot
relevant securities, in addition to the authority under resolution
3.
|
6,821,544
|
96.75%
|
229,403
|
3.25%
|
12,535
|
7,050,947
|
|
Further Special Resolutions
|
|
|
|
|
|
|
|
16. To dis-apply pre-emption rights generally,
in addition to the authority under resolution 4.
|
6,747,378
|
95.70%
|
303,569
|
4.30%
|
12,535
|
7,050,947
|
|
17. To dis-apply pre-emption rights pursuant to
allotments to finance acquisitions and capital investments, in
addition to the authority under resolution 4.
|
6,743,726
|
95.64%
|
307,221
|
4.36%
|
12,535
|
7,050,947
|
* "Votes For"
include votes giving the Chairman discretion.
**
Percentages exclude "Votes Withheld".
*** "Votes
Withheld" are not votes in law and do not count in the number of
votes counted for or against a resolution.
**** "Total
votes cast" do not include withheld
votes.
Terms used but not defined in this announcement
shall have the meanings given to such terms in the section headed
'Definitions' in the Company's announcement released at 7:01 a.m.
on 4 November 2024.
--Ends--
Enquiries:
|
Feedback
plc
Tom Oakley, CEO
Anesh Patel, CFO
|
+44 (0) 20 3997 7634
IR@fbk.com
|
|
|
|
|
Panmure
Liberum Limited (NOMAD and Broker)
Emma Earl/ Mark Rogers (Corporate
Finance)
Rupert Dearden (Corporate Broking)
|
+44 (0)20 7886 2500
|
|
|
|
|
Walbrook PR
Ltd;
|
Tel: 020 7933 8780 or
feedbackplc@walbrookpr.com
|
|
Nick Rome/Joe Walker
|
07748 325 236 or 07407 020 470
|
About
Feedback
Feedback plc helps clinical teams to make
better decisions faster for patients. We design products that
enhance clinician access to patient data and to their colleagues.
Our unique approach centres around individual patient episodes,
into which we pull relevant clinical data from hospital systems and
around which we build remote clinical teams for collaboration. As a
result, we produce a digital infrastructure that makes patient data
available to clinicians in multiple settings, in a format that
enables them to meaningfully interact with it, providing
flexibility to clinicians and free movement of patients between
provider settings - clinicians can practice from anywhere and
patients can attend any care provider for treatment, with greater
connectivity across organisations.
Our products Bleepa® and CareLocker® work
together to deliver unparalleled value to our customers. Bleepa® is
our application layer and sits on top of CareLocker® as our data
layer. Bleepa® is a clinician facing platform that displays
clinical results from a patient's CareLocker® at a certified and
regulated quality, that is suitable for clinical use and enables
dialogue on a patient-by-patient basis with colleagues through a
secure, auditable chat interface that links back to the patient
medical record. The CareLocker® data storage model is built around
the patient. Our vision is one where relevant clinical data is
always available to the patient as well as to any care setting that
they may attend - a federated data architecture with the patient as
the tenant.
The Company has a number of growth
opportunities domestically and internationally across a range of
markets including the NHS and private healthcare providers and its
highly scalable Software as a Service ("SaaS")-based model is
expected to provide increasing levels of revenue visibility as the
Company grows its customer base.